|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: VEGFC |
Gene summary for VEGFC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | VEGFC | Gene ID | 7424 |
| Gene name | vascular endothelial growth factor C | |
| Gene Alias | Flt4-L | |
| Cytomap | 4q34.3 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P49767 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7424 | VEGFC | C04 | Human | Oral cavity | OSCC | 1.47e-19 | 1.02e+00 | 0.2633 |
| 7424 | VEGFC | C21 | Human | Oral cavity | OSCC | 3.49e-40 | 1.24e+00 | 0.2678 |
| 7424 | VEGFC | C30 | Human | Oral cavity | OSCC | 1.23e-39 | 1.35e+00 | 0.3055 |
| 7424 | VEGFC | C51 | Human | Oral cavity | OSCC | 9.54e-10 | 4.78e-01 | 0.2674 |
| 7424 | VEGFC | C06 | Human | Oral cavity | OSCC | 1.26e-03 | 9.43e-01 | 0.2699 |
| 7424 | VEGFC | SYSMH3 | Human | Oral cavity | OSCC | 2.97e-17 | 5.72e-01 | 0.2442 |
| 7424 | VEGFC | SYSMH5 | Human | Oral cavity | OSCC | 4.32e-02 | 1.38e-01 | 0.0647 |
| 7424 | VEGFC | male-WTA | Human | Thyroid | PTC | 6.10e-27 | 8.02e-02 | 0.1037 |
| 7424 | VEGFC | PTC01 | Human | Thyroid | PTC | 6.64e-06 | -8.21e-03 | 0.1899 |
| 7424 | VEGFC | PTC04 | Human | Thyroid | PTC | 2.33e-11 | 6.51e-02 | 0.1927 |
| 7424 | VEGFC | PTC05 | Human | Thyroid | PTC | 6.52e-14 | 5.55e-01 | 0.2065 |
| 7424 | VEGFC | PTC06 | Human | Thyroid | PTC | 4.20e-17 | 4.19e-01 | 0.2057 |
| 7424 | VEGFC | PTC07 | Human | Thyroid | PTC | 1.06e-24 | 4.27e-01 | 0.2044 |
| 7424 | VEGFC | ATC09 | Human | Thyroid | ATC | 2.24e-05 | 1.81e-02 | 0.2871 |
| 7424 | VEGFC | ATC11 | Human | Thyroid | ATC | 9.19e-03 | 3.90e-01 | 0.3386 |
| 7424 | VEGFC | ATC12 | Human | Thyroid | ATC | 3.00e-11 | 1.33e-01 | 0.34 |
| 7424 | VEGFC | ATC1 | Human | Thyroid | ATC | 4.62e-06 | 5.52e-02 | 0.2878 |
| 7424 | VEGFC | ATC2 | Human | Thyroid | ATC | 9.47e-03 | 4.50e-01 | 0.34 |
| 7424 | VEGFC | ATC3 | Human | Thyroid | ATC | 2.78e-05 | 3.07e-01 | 0.338 |
| 7424 | VEGFC | ATC4 | Human | Thyroid | ATC | 1.89e-13 | 2.23e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190495119 | Oral cavity | OSCC | positive regulation of establishment of protein localization | 196/7305 | 319/18723 | 2.89e-16 | 2.20e-14 | 196 |
| GO:005122219 | Oral cavity | OSCC | positive regulation of protein transport | 187/7305 | 303/18723 | 7.37e-16 | 5.49e-14 | 187 |
| GO:007048219 | Oral cavity | OSCC | response to oxygen levels | 200/7305 | 347/18723 | 1.17e-12 | 5.13e-11 | 200 |
| GO:000166619 | Oral cavity | OSCC | response to hypoxia | 177/7305 | 307/18723 | 2.21e-11 | 7.50e-10 | 177 |
| GO:003629319 | Oral cavity | OSCC | response to decreased oxygen levels | 182/7305 | 322/18723 | 1.14e-10 | 3.41e-09 | 182 |
| GO:00107209 | Oral cavity | OSCC | positive regulation of cell development | 159/7305 | 298/18723 | 3.06e-07 | 4.66e-06 | 159 |
| GO:00467779 | Oral cavity | OSCC | protein autophosphorylation | 123/7305 | 227/18723 | 2.31e-06 | 2.93e-05 | 123 |
| GO:004586016 | Oral cavity | OSCC | positive regulation of protein kinase activity | 194/7305 | 386/18723 | 3.90e-06 | 4.59e-05 | 194 |
| GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
| GO:000268714 | Oral cavity | OSCC | positive regulation of leukocyte migration | 78/7305 | 135/18723 | 7.43e-06 | 8.08e-05 | 78 |
| GO:003367418 | Oral cavity | OSCC | positive regulation of kinase activity | 228/7305 | 467/18723 | 8.31e-06 | 8.90e-05 | 228 |
| GO:00507696 | Oral cavity | OSCC | positive regulation of neurogenesis | 120/7305 | 225/18723 | 8.45e-06 | 9.02e-05 | 120 |
| GO:19908237 | Oral cavity | OSCC | response to leukemia inhibitory factor | 58/7305 | 95/18723 | 1.10e-05 | 1.14e-04 | 58 |
| GO:19908307 | Oral cavity | OSCC | cellular response to leukemia inhibitory factor | 57/7305 | 94/18723 | 1.75e-05 | 1.71e-04 | 57 |
| GO:005067310 | Oral cavity | OSCC | epithelial cell proliferation | 212/7305 | 437/18723 | 2.82e-05 | 2.61e-04 | 212 |
| GO:000166719 | Oral cavity | OSCC | ameboidal-type cell migration | 228/7305 | 475/18723 | 3.46e-05 | 3.10e-04 | 228 |
| GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
| GO:00507679 | Oral cavity | OSCC | regulation of neurogenesis | 179/7305 | 364/18723 | 4.49e-05 | 3.84e-04 | 179 |
| GO:000164910 | Oral cavity | OSCC | osteoblast differentiation | 118/7305 | 229/18723 | 7.51e-05 | 5.85e-04 | 118 |
| GO:001063118 | Oral cavity | OSCC | epithelial cell migration | 174/7305 | 357/18723 | 1.04e-04 | 7.70e-04 | 174 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa046689 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
| hsa0451019 | Oral cavity | OSCC | Focal adhesion | 128/3704 | 203/8465 | 1.71e-08 | 1.63e-07 | 8.31e-08 | 128 |
| hsa049339 | Oral cavity | OSCC | AGE-RAGE signaling pathway in diabetic complications | 69/3704 | 100/8465 | 2.61e-07 | 1.65e-06 | 8.41e-07 | 69 |
| hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
| hsa049267 | Oral cavity | OSCC | Relaxin signaling pathway | 74/3704 | 129/8465 | 1.20e-03 | 3.37e-03 | 1.72e-03 | 74 |
| hsa0401518 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
| hsa0466816 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
| hsa04510110 | Oral cavity | OSCC | Focal adhesion | 128/3704 | 203/8465 | 1.71e-08 | 1.63e-07 | 8.31e-08 | 128 |
| hsa0493316 | Oral cavity | OSCC | AGE-RAGE signaling pathway in diabetic complications | 69/3704 | 100/8465 | 2.61e-07 | 1.65e-06 | 8.41e-07 | 69 |
| hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
| hsa0492615 | Oral cavity | OSCC | Relaxin signaling pathway | 74/3704 | 129/8465 | 1.20e-03 | 3.37e-03 | 1.72e-03 | 74 |
| hsa0401519 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| VEGFC | KDR | VEGFC_VEGFR2 | VEGF | Breast | Healthy |
| VEGFC | KDR | VEGFC_VEGFR2 | VEGF | Cervix | CC |
| VEGFC | FLT4 | VEGFC_VEGFR3 | VEGF | Endometrium | ADJ |
| VEGFC | KDR | VEGFC_VEGFR2 | VEGF | Endometrium | ADJ |
| VEGFC | FLT4_KDR | VEGFC_VEGFR2R3 | VEGF | Endometrium | ADJ |
| VEGFC | FLT4 | VEGFC_VEGFR3 | VEGF | Endometrium | AEH |
| VEGFC | KDR | VEGFC_VEGFR2 | VEGF | Endometrium | AEH |
| VEGFC | FLT4_KDR | VEGFC_VEGFR2R3 | VEGF | Endometrium | AEH |
| VEGFC | FLT4 | VEGFC_VEGFR3 | VEGF | Endometrium | EEC |
| VEGFC | KDR | VEGFC_VEGFR2 | VEGF | Endometrium | EEC |
| VEGFC | FLT4_KDR | VEGFC_VEGFR2R3 | VEGF | Endometrium | EEC |
| VEGFC | FLT4 | VEGFC_VEGFR3 | VEGF | Esophagus | ESCC |
| VEGFC | KDR | VEGFC_VEGFR2 | VEGF | Esophagus | ESCC |
| VEGFC | FLT4_KDR | VEGFC_VEGFR2R3 | VEGF | Esophagus | ESCC |
| VEGFC | KDR | VEGFC_VEGFR2 | VEGF | GC | GC |
| VEGFC | FLT4 | VEGFC_VEGFR3 | VEGF | HNSCC | OSCC |
| VEGFC | KDR | VEGFC_VEGFR2 | VEGF | HNSCC | OSCC |
| VEGFC | FLT4_KDR | VEGFC_VEGFR2R3 | VEGF | HNSCC | OSCC |
| VEGFC | FLT4 | VEGFC_VEGFR3 | VEGF | HNSCC | Precancer |
| VEGFC | KDR | VEGFC_VEGFR2 | VEGF | HNSCC | Precancer |
| Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| VEGFC | SNV | Missense_Mutation | novel | c.1061N>G | p.Asn354Ser | p.N354S | P49767 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-OL-A5D7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| VEGFC | SNV | Missense_Mutation | rs566826535 | c.181N>T | p.Arg61Trp | p.R61W | P49767 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| VEGFC | SNV | Missense_Mutation | novel | c.139G>A | p.Glu47Lys | p.E47K | P49767 | protein_coding | tolerated(0.12) | benign(0.231) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| VEGFC | SNV | Missense_Mutation | rs752936139 | c.1186G>A | p.Glu396Lys | p.E396K | P49767 | protein_coding | tolerated(0.14) | benign(0.02) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| VEGFC | SNV | Missense_Mutation | novel | c.139N>C | p.Glu47Gln | p.E47Q | P49767 | protein_coding | tolerated(0.17) | benign(0.077) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| VEGFC | SNV | Missense_Mutation | novel | c.514N>A | p.Gln172Lys | p.Q172K | P49767 | protein_coding | tolerated(0.22) | possibly_damaging(0.528) | TCGA-JW-A69B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| VEGFC | SNV | Missense_Mutation | novel | c.919C>T | p.His307Tyr | p.H307Y | P49767 | protein_coding | tolerated(0.16) | possibly_damaging(0.753) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| VEGFC | SNV | Missense_Mutation | novel | c.922A>G | p.Lys308Glu | p.K308E | P49767 | protein_coding | tolerated(0.18) | benign(0.341) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| VEGFC | SNV | Missense_Mutation | novel | c.277A>G | p.Asn93Asp | p.N93D | P49767 | protein_coding | tolerated(0.26) | benign(0.01) | TCGA-AA-3842-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PD |
| VEGFC | SNV | Missense_Mutation | novel | c.1244N>T | p.Arg415Ile | p.R415I | P49767 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7424 | VEGFC | GROWTH FACTOR, TRANSPORTER, DRUGGABLE GENOME | bevacizumab | BEVACIZUMAB | 20124951 | |
| 7424 | VEGFC | GROWTH FACTOR, TRANSPORTER, DRUGGABLE GENOME | aflibercept | AFLIBERCEPT | 20124951 | |
| 7424 | VEGFC | GROWTH FACTOR, TRANSPORTER, DRUGGABLE GENOME | BEVACIZUMAB | BEVACIZUMAB | ||
| 7424 | VEGFC | GROWTH FACTOR, TRANSPORTER, DRUGGABLE GENOME | VGX-100 | VGX-100 | ||
| 7424 | VEGFC | GROWTH FACTOR, TRANSPORTER, DRUGGABLE GENOME | inhibitor | SORAFENIB TOSYLATE | ||
| 7424 | VEGFC | GROWTH FACTOR, TRANSPORTER, DRUGGABLE GENOME | inhibitor | ENDOSTATIN (84-114)-NH2 (JKC367) | ||
| 7424 | VEGFC | GROWTH FACTOR, TRANSPORTER, DRUGGABLE GENOME | inhibitor | CHEMBL2108313 | CONBERCEPT | |
| 7424 | VEGFC | GROWTH FACTOR, TRANSPORTER, DRUGGABLE GENOME | LENALIDOMIDE | LENALIDOMIDE | ||
| 7424 | VEGFC | GROWTH FACTOR, TRANSPORTER, DRUGGABLE GENOME | SUNITINIB | SUNITINIB | 21787417 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |